RBC Sees Durable Growth Profile at Becton Dickinson (BDX), Raises Target

Core Viewpoint - Becton, Dickinson and Company (NYSE:BDX) is recognized as one of the best income stocks to buy now, with a positive outlook for growth in the medical supplies and devices sector [1]. Group 1: Price Target and Growth Outlook - RBC Capital raised its price target for Becton Dickinson to $210 from $202, maintaining a Sector Perform rating, indicating a constructive view on the company's growth potential [2]. - The firm anticipates a mid-single-digit growth rate for Becton Dickinson, supported by a durable core business and a high level of recurring revenue [2]. Group 2: Legal Challenges - Becton Dickinson is facing a lawsuit from Tela Bio, alleging anticompetitive behavior in the US surgical hernia mesh market, which could impact its market position [3][4]. - The lawsuit claims that Becton Dickinson's practices have led to higher prices for patients and care providers, and that it has used long-term contracts to restrict competition [5]. Group 3: Company Overview - Becton, Dickinson and Company is a global medical technology company that designs and manufactures medical devices, instrument systems, reagents, and analytics used across healthcare settings worldwide [6].